Expansion potential Grünenthal operates in 28 countries with products available in around 100 markets and revenues of €1.8 billion in 2025, signaling opportunities to introduce or expand pain-management solutions and related therapies across its international footprint.

Strategic partnerships Recent collaborations and disputes indicate openness to external partnerships and licensing, including a CNATM joint effort and Brazil-focused activity with Merz Therapeutics; target these channels for co-development, distribution agreements, or regional manufacturing opportunities.

Innovation focus Active development of novel targets such as nociceptin receptor agonists and commitment to state‑of‑the‑art technologies position Grünenthal as a partner for advanced formulations, digital health integration, and high-value R&D collaborations.

Manufacturing expansion Significant investment in production facilities, including a recent $30 million facility in Ecuador, suggests a willingness to scale manufacturing capacity; offer API supply, contract manufacturing, and supply-chain resilience solutions.

Digital and data readiness Adoption of tech stack elements like SAP Concur, SharePoint, SQL Server, and AI tools indicates receptiveness to digital transformation; present integrated analytics, compliance, and data-management solutions tailored to global pharmaceutical operations.